Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M21,277Revenue (TTM) $M1,557Net Margin (%)-17.7Altman Z-Score6.8
Enterprise Value $M23,756EPS (TTM) $-1.1Operating Margin %-8.7Piotroski F-Score4
P/E(ttm)--Beneish M-Score-0.8Pre-tax Margin (%)-13.9Higher ROA y-yY
Price/Book20.110-y EBITDA Growth Rate %--Quick Ratio2.4Cash flow > EarningsY
Price/Sales18.05-y EBITDA Growth Rate %--Current Ratio2.5Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-11.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-28.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M247ROIC % (ttm)-19.9Gross Margin Increase y-yN

Gurus Latest Trades with VRTX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VRTXVanguard Health Care Fund 2016-03-31 Add0.5%$78.4 - $125.83
($91.01)
$ 96.216%Add 28.91%12,668,241
VRTXLeucadia National 2016-03-31 Buy 0.04%$78.4 - $125.83
($91.01)
$ 96.216%New holding3,300
VRTXJohn Paulson 2016-03-31 Add0.01%$78.4 - $125.83
($91.01)
$ 96.216%Add 32.54%61,500
VRTXJoel Greenblatt 2016-03-31 Reduce-0.01%$78.4 - $125.83
($91.01)
$ 96.216%Reduce -57.21%5,046
VRTXKen Fisher 2016-03-31 Reduce$78.4 - $125.83
($91.01)
$ 96.216%Reduce -7.00%5,155
VRTXVanguard Health Care Fund 2015-12-31 Add0.1%$109.03 - $133.26
($121.16)
$ 96.21-21%Add 4.34%9,827,411
VRTXJohn Paulson 2015-12-31 Buy 0.04%$109.03 - $133.26
($121.16)
$ 96.21-21%New holding46,400
VRTXJoel Greenblatt 2015-12-31 Buy 0.02%$109.03 - $133.26
($121.16)
$ 96.21-21%New holding11,793
VRTXKen Fisher 2015-12-31 Add$109.03 - $133.26
($120.93)
$ 96.21-20%Add 12.48%5,543
VRTXVanguard Health Care Fund 2015-09-30 Reduce-0.03%$98.5 - $141.48
($128.47)
$ 96.21-25%Reduce -1.21%9,418,411
VRTXKen Fisher 2015-09-30 Add$98.5 - $141.48
($128.47)
$ 96.21-25%Add 12.56%4,928
VRTXGeorge Soros 2015-06-30 Sold Out -0.07%$116.43 - $135.82
($125.88)
$ 96.21-24%Sold Out0
VRTXKen Fisher 2015-06-30 Reduce$116.43 - $135.82
($125.88)
$ 96.21-24%Reduce -0.18%4,378
VRTXVanguard Health Care Fund 2015-03-31 Reduce-0.08%$107.88 - $134.25
($119.81)
$ 96.21-20%Reduce -2.80%9,533,911
VRTXGeorge Soros 2015-03-31 Buy 0.07%$107.88 - $134.25
($119.81)
$ 96.21-20%New holding56,912
VRTXKen Fisher 2015-03-31 Add$107.88 - $134.25
($119.81)
$ 96.21-20%Add 0.18%4,386
VRTXVanguard Health Care Fund 2014-12-31 Reduce-0.58%$101.1 - $120.78
($112.61)
$ 96.21-15%Reduce -16.93%9,808,860
VRTXKen Fisher 2014-09-30 Reduce$84.74 - $113.9
($94.97)
$ 96.211%Reduce -31.99%4,593
VRTXVanguard Health Care Fund 2014-06-30 Add0.04%$62.44 - $94.68
($70.13)
$ 96.2137%Add 1.54%11,807,500
VRTXGeorge Soros 2014-06-30 Sold Out -0.01%$62.44 - $93.77
($69.73)
$ 96.2138%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VRTX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


VRTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BOGER JOSHUA SDirector 2016-07-20Sell6,500$90.336.51view
BOGER JOSHUA SDirector 2016-07-13Sell6,500$88.818.33view
BOGER JOSHUA SDirector 2016-07-06Sell5,140$88.998.11view
BOGER JOSHUA SDirector 2016-06-29Sell5,130$84.8213.43view
BOGER JOSHUA SDirector 2016-06-22Sell5,130$86.6111.08view
BOGER JOSHUA SDirector 2016-06-15Sell5,130$91.185.52view
BOGER JOSHUA SDirector 2016-06-08Sell5,130$94.951.33view
BOGER JOSHUA SDirector 2016-06-01Sell5,130$93.652.73view
BOGER JOSHUA SDirector 2016-05-25Sell5,130$89.097.99view
BOGER JOSHUA SDirector 2016-05-18Sell5,130$81.1818.51view

Quarterly/Annual Reports about VRTX:

    News about VRTX:

    Articles On GuruFocus.com
    Vanguard Health Care Fund Ups Stake in High-Conviction Stocks May 10 2016 
    Vanguard Boosts Stake in Incyte in 1st Quarter May 02 2016 
    Kyle Bass Sells Stakes in 11 Health Care Companies Mar 01 2016 
    Lee Ainslie Adds 90 New Stocks to His Portfolio Within the First Quarter May 20 2015 
    Analysts Confident That Vertex Pharmaceuticals' CF Drug Will Receive FDA Approval May 13 2015 
    Fate Of Cystic Fibrosis Drug By Vertex Is Now Dependent On FDA Approval May 13 2015 
    J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
    William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015 Dec 23 2014 
    Weekly CFO Sells Highlight: Texas Instruments Inc, Royal Caribbean Cruises Ltd, Vertex Pharmaceutica Nov 09 2014 
    Weekly CFO Sells Highllight: Facebook Inc, Vertex Pharmaceuticals Inc, Nike Inc. Oct 05 2014 

    More From Other Websites
    Vertex (VRTX) Posts Narrower Q2 Loss, Revenues Fall Short Jul 28 2016
    Edited Transcript of VRTX earnings conference call or presentation 27-Jul-16 8:30pm GMT Jul 28 2016
    Nivalis (NVLS): Can the Stock Surprise This Earnings Season? Jul 27 2016
    Vertex Pharmaceuticals reports 2Q loss Jul 27 2016
    Vertex Pharmaceuticals reports 2Q loss Jul 27 2016
    [$$] Vertex Pharma Loss Narrows as Cystic Fibrosis Drug Sales Grow Jul 27 2016
    Vertex Reports Second Quarter 2016 Financial Results Jul 27 2016
    VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 27 2016
    4:08 pm Vertex Pharma beats by $0.04, reports revs in-line; reaffirms FY16 product revenue guidance Jul 27 2016
    Vertex Reports Second Quarter 2016 Financial Results Jul 27 2016
    Q2 2016 Vertex Pharmaceuticals Inc Earnings Release - After Market Close Jul 27 2016
    5 Drug Stocks' Earnings on Jul 27: AMGN, VRTX & More Jul 26 2016
    Understanding Improvement in Vertex Pharmaceuticals’s PE Multiple Jul 25 2016
    Orkambi Launch Impacts Vertex Pharmaceuticals’s Major Revenue Contributor Jul 25 2016
    Vertex (VRTX) to Report Q2 Earnings: Is a Surprise in Store? Jul 25 2016
    How Much Will Orkambi Fetch for Vertex Pharmaceuticals in 2Q16? Jul 22 2016
    Is Vertex Pharmaceuticals Exposed to Drug Pricing Risks? Jul 22 2016
    Wall Street Looks for Vertex Pharmaceuticals to Break Even in 2Q16 Jul 21 2016
    How Analysts Think Investors Should Play Vertex Pharmaceuticals Jul 21 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)